Oppenheimer analyst Matthew Biegler lowered the firm’s price target on Oric Pharmaceuticals (ORIC) to $12 from $15 and keeps an Outperform rating on the shares following quarterly results. The firm says key milestones remain on track; most immediately dose-escalation results from the combination of ORIC-944 with apa/darolutamide.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORIC: